Windtree Therapeutics FY2024 net loss $1.8M; cash $1.8M; pivots to revenue-generating acquisitions

WINDTREE THERAPEUTICS INC /DE/

Net loss $1.8M vs $20.3M in 2023; loss per basic share $104.35 on $5.5M net loss attributable to common.
Cash and equivalents $1.8M at Dec 31, 2024; raised ~$2.3M post-period, funding operations only through April 2025.
New corporate strategy: use equity to acquire small biotech firms with FDA-approved products; signed Evofem deal for PHEXXI distribution.
Positive Phase 2 SEISMiC Extension for istaroxime in early cardiogenic shock; SEISMiC C trial enrolling, interim data in Q3 2025.
R&D spend rose to $16.3M from $8.3M, driven by $7.5M Varian IPR&D charge and increased istaroxime development costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.